Good Shroom Co (OTC:TGSHF) Stock, Quote.Headers.trade-ideas

The Good Shroom Co Inc operates a portfolio of brands that include traditional cannabis and beverage products. The company exists to promote the use of mushrooms through its brands; The Teo Nan brand is a functional mushroom beverage range serving the American and Canadian wellness market via DTC and retail; The Nordique Royale is a premium quality hash; and The Velada brand is a range of CBD-infused functional mushroom beverages serving the Canadian legal cannabis market. It derives maximum revenue from Canada and also has its presence in USA.

THE GOOD SHROOM CO INC by THE GOOD SHROOM CO INC

The Good Shroom Co Inc

Earnings

News

XCHG Q2 2024 EPS $(0.002) Down From $0.001 YoY; Revenue $9M Down From $12.20M  YoY

Insider Trades

Alaska Air Group CEO And President Benito Minicucci Sold 30,000 Shares At An Average Price Of $65.07/Share

Offerings

TKO Group Files For Mixed Shelf; Size Not Disclosed

Amrep (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXR#NYSE">AXR</a>) reported quarterly earnings of $0.75 per share. This is a 257.14 percent increase over earnings of $0.21 per share from the same period last year. The company reported $11.91 million in sales this quarter. This is a 34.47 percent increase over sales of $8.85 million the same period last year.

Amrep Q2 EPS $0.75 Up From $0.21 YoY, Sales $11.91M Up From $8.85M YoY

What Happened: OpenAI has responded to Elon Musk's legal efforts to prevent its transition to a fully for-profit structure, accusing the billionaire of undermining the company after failing to gain control <a href="https://www.benzinga.com/topic/openai">during earlier negotiations.</a> 
In a recent blog post, OpenAI revealed that Musk had initially supported restructuring the organization into a for-profit entity in 2017 but abandoned the idea when his proposal to hold majority control was rejected. "[Musk] walked away and told us we would fail," OpenAI stated, <a href="https://www.cnbc.com/2024/12/13/openai-says-elon-musk-wanted-it-to-be-for-profit-in-2017.html">CNBC </a>reports.
The dispute stems from Musk's broader critique of OpenAI, which he co-founded, and its growing relationship with Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). Musk has filed for a court injunction, claiming the company's shift betrays its original nonprofit mission. 
Musk's complaints also allege that Microsoft benefits from restricted access to advanced AI models <a href="https://www.benzinga.com/24/12/42382569/elon-musk-asks-was-it-ever-not-a-lie-as-he-accuses-openai-of-selling-out-to-microsoft-and-betraying-its-founding-mission">while stifling competition.</a> He voiced concerns about monopolistic behavior in the industry, which have been central to his ongoing legal disputes with OpenAI and Microsoft.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42489039/feds-december-meeting-could-crush-rate-cut-optimism-for-2025">Fed&#8217;s December Meeting Could Crush Rate Cut Optimism For 2025</a>
OpenAI, however, maintains that the transformation aligns with its mission of advancing artificial intelligence responsibly, while remaining competitive in an evolving market.
Why It Matters: Musk's criticisms highlight growing tension within the AI industry as organizations navigate commercial pressures and ethical concerns. OpenAI has become a dominant force in generative AI, valued at $157 billion and attracting substantial investments, including $14 billion from Microsoft.
Musk, meanwhile, has positioned his own venture, xAI, as a rival, raising billions and launching its Grok chatbot. The unfolding legal battle underscores the high stakes in a sector expected to reach $1 trillion in revenue within a decade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42489019/teslas-76-post-trump-rally-bullish-run-or-signal-to-cash-out">Tesla&#8217;s 76% Post-Trump Rally: Bullish Run Or Signal To Cash Out?</a></li>
</ul>
Photo: Shutterstock

Legal

Tech

MSFT

TSLA

OpenAI Challenges Musk's Lawsuit, Reveals 2017 Profit Talks

Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) has outperformed the market over the past 5 years by 39.72% on an annualized basis producing an average annual return of 53.31%. Currently, Abercrombie &amp; Fitch has a market capitalization of $7.15 billion. 
Buying $1000 In ANF: If an investor had bought $1000 of ANF stock 5 years ago, it would be worth $8,484.24 today based on a price of $142.03 for ANF at the time of writing.
<h3>Abercrombie &amp; Fitch's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734126317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Abercrombie & Fitch 5 Years Ago Would Be Worth This Much Today

Scale AI, a San Francisco-based <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence</a> startup with a $13.8 billion valuation and high-profile partnerships across the tech industry, is facing a class-action lawsuit alleging wage theft and worker misclassification.
The lawsuit, filed Tuesday in San Francisco Superior Court by former contractor Steve McKinney, names Scale AI and its top executives, including 27-year-old billionaire CEO Alexandr Wang, as defendants. 
McKinney alleges Scale built its success by exploiting workers, accusing the company of practices like unpaid labor, denied overtime and unfair reassignments. As such, the lawsuit seeks class-action certification, restitution, punitive damages and changes to Scale's worker classification model, <a href="https://www.sfgate.com/tech/article/sf-tech-startup-scale-ai-sued-wage-theft-19976761.php?sid=65d21e793be09a5bd409b575&amp;utm_source=newsletter&amp;utm_medium=email&amp;utm_term=briefing&amp;utm_campaign=sfgt%20%7C%20the%20daily&amp;stn=nf">according</a> to SFGate, which reported this on Friday.
"Scale AI is the sordid underbelly propping up the generative AI industry," the complaint states, describing the company's control over contractors as "Orwellian." It accuses Scale of monitoring contractors with tools that take periodic screenshots of their computer use, docking pay for tasks that exceed estimated time limits and reassigning workers to lower-paying projects. 
The lawsuit also claims Scale violated California's "ABC" test for independent contractors, asserting that workers like McKinney should be classified as employees.
Scale spokesperson Tom Channick responded to the allegations. "We do not comment on litigation but are committed to ensuring we are in full compliance with all applicable laws and regulations," he told SFGate in a statement, adding that contractors working for Scale enjoy flexible, supplemental income and earn significant sums.
<h1 class="wp-block-heading">Dark Side Of AI&#8217;s Rapid Growth</h1>
The lawsuit underscores the darker side of the AI industry's rapid growth, noting the disturbing and at times traumatic tasks contractors are sometimes assigned. McKinney's complaint alleges, for example, that workers are assigned to projects "that deal with obscene and distressing subject matter, where Taskers must provide responses to prompts regarding extremely disturbing topics." The document provides the example of "sexual intercourse with dead animals."
Channick countered the claims, stating that workers receive advanced notice about sensitive tasks, can opt out at any time and have access to wellness programs. However, McKinney's attorney, Glenn Danas, said in a news release quoted by SFGate that such tasks are traumatizing for workers. "If companies like Scale AI are not held accountable, humans will continue to be exploited to train this unregulated technology for profit," Danas said.
<h1 class="wp-block-heading">Scale&#8217;s Meteoric Rise</h1>
Scale AI, founded in 2016, positioned itself as a frontrunner in the AI&nbsp;industry,&nbsp;years before&nbsp;OpenAI's&nbsp;ChatGPT gained popularity. According to <a href="https://fortune.com/2024/05/21/scale-ai-funding-valuation-ceo-alexandr-wang-profitability/">Fortune</a>, Scale contractors annotated images for Cruise and Waymo, aiding autonomous vehicle tech and supplied data for OpenAI. With a $13.8 billion valuation, Scale partners with Meta Platforms, Microsoft, Nvidia and the Department of Defense.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42476730/peter-thiels-founders-fund-leads-600m-crusoe-investment-betting-big-on-ai-infrastructure">Peter Thiel Says, &#8216;The Biggest Risk With AI Is That We Don&#8217;t Go Big Enough&#8217; As His Founders Fund Leads $600 Million Crusoe Investment</a></li>
</ul>
Image generated with AI

NVDA

Wage Theft Allegations Target $13.8B Tech Giant Scale AI

The tech-heavy Nasdaq 100 index – as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – extended its relentless climb this week, setting new record highs and nearing the 22,000-point milestone, fueled by strong investor optimism in the Magnificent Seven tech giants and the transformative <a href="https://www.benzinga.com/news/large-cap/24/12/42447567/magnificent-seven-tech-titans-hit-182-trillion-market-cap-alphabet-amazon-apple-meta-tesla-jointly-notch-all-time-highs">potential of artificial intelligence.</a>
Year-to-date, the index has posted a robust 30% gain, on track to outperform the S&amp;P 500 for the ninth time in the last decade.
Since the start of 2023, the Nasdaq 100 is on track to double, nearing a 100% gain &#8211; a performance last achieved in 2019-2020 with a 102% rise and previously hit during the dot-com boom of 1998-1999.
Notably, five out of the seven Magnificent Seven stocks— Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — achieved fresh record highs this week. The combined market capitalization of the group exceeded $18 trillion, surpassing China's gross domestic product at the end of 2023.
Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) emerged as the week's standout performer, soaring after a strong quarterly earnings beat and delivering upbeat AI-driven guidance for the coming year. The rally propelled the chipmaker into the exclusive $1 trillion market-cap club, making it the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488220/broadcom-hits-1-trillion-milestone-the-next-magnificent-tech-giant">eighth-largest publicly traded company.</a>
Inflation data released during the week raised some red flags. Consumer inflation rose 2.7% year-over-year in November, in line with expectations, but producer inflation jumped to 3% year-over-year, <a href="https://www.benzinga.com/news/treasuries/24/12/42460477/producer-inflation-rises-more-than-expected-to-3-in-november-cast-shadow-on-further-disinflation-progress">exceeding estimates of 2.6%.</a> This marked the sharpest increase since February 2023, raising concerns about potential cost pass-throughs to consumers.
Investors are fully pricing in a 25-basis-point interest rate cut at the Federal Reserve&#8217;s Dec. 18 meeting. Yet policymakers may signal fewer rate cuts for 2025 — potentially just three — while leaving open the possibility of a pause as early as January.
You may have missed&#8230; 
<h3 class="wp-block-heading">Trump Rings NYSE</h3>
President-elect Donald Trump rang the New York Stock Exchange opening bell on Thursday, expressing confidence in a strong U.S. economy. Trump was named TIME Person of the Year for the second time.
<h3 class="wp-block-heading">GM Robotaxi Exit</h3>
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) plans to abandon its robotaxi ambitions, aiming to save $1 billion annually and potentially license Tesla&#8217;s Full Self-Driving technology, <a href="https://www.benzinga.com/markets/equities/24/12/42429325/robotaxi-exit-to-clear-the-way-for-gm-to-license-tesla-fsd-says-gary-black-move-will-save-the-mary-barra-led-company-1b-a-year">says analyst Gary Black.</a>
<h3 class="wp-block-heading">Google&#8217;s Quantum Leap</h3>
Alphabet's new Willow quantum chip showcases cutting-edge innovation. Analysts praise Google for advancing technology leadership, signaling potential breakthroughs in computing power <a href="https://www.benzinga.com/24/12/42447332/alphabets-quantum-willow-chip-wows-analyst-google-at-the-leading-edge-of-technology-innovation">and commercial applications.</a>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42489039/feds-december-meeting-could-crush-rate-cut-optimism-for-2025">Fed&#8217;s December Meeting Could Crush Rate Cut Optimism For 2025</a></li>
</ul>

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

AAPL

AMZN

AVGO

GOOGL

AI-Driven Rally Pushes Tech Stocks To Records, Broadcom Enters Trillion-Dollar Club, Inflation Data Flashes Warning Signal: This Week In The Markets

SDOT

Sadot Group Files For Prospectus Relates To Resale, From Time To Time, Of Up To 914,634 Shares Of Common Stock By Selling Stockholders

FBRX

Forte Biosciences Files For Offer & Resale From Time To Time Of Up To 9.5M Shares Of Common Stock By Selling Stockholders

Super League Enterprise Files For Mixed Shelf Of Up To $100M

SMX Announces Receipt Of Nasdaq Listing Delinquency Notice

Preliminary results indicate approximately 70% of retail vote for new voices on Board of Directors, not including votes cast by members of the Dream Chasers Group
Calls on Donald Felix and Carver Board of Directors to do right by shareholders
Demands answers to why Board of Directors vote was extended by 45 minutes
Demands disclosure of any high-pressure sales calls to certain large shareholders, including any offers, promises or assurances made to shareholders to sway vote at last minute
Calls on Board to hear shareholders, appoint Jeffrey &quot;Jeff&quot; Anderson and Jeffrey Bailey to the Board
NEW YORK, Dec. 13, 2024 /PRNewswire/ -- Following a concerning set of unconventional practices at the Carver&nbsp;Bancorp, Inc. (&quot;Carver,&quot; or the &quot;Company&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARV#NASDAQ">CARV</a>) Annual Meeting of Shareholders (the &quot;Meeting&quot;) on December 12, 2024, Dream Chasers Capital Group LLC (&quot;Dream Chasers&quot;) urged Carver Chief Executive Officer Donald Felix and the Board of Directors (the &quot;Board&quot;) to provide clarity, certainty and transparency to shareholders.&nbsp; Preliminary results indicate that approximately 70% of retail shareholders supported Jeffrey &quot;Jeff&quot; Anderson and/or Jeffrey Bailey for election to the Board.

Management

CARV

Dream Chasers Capital Group Calls On Carver Bancorp Board To Appoint Jeffrey "Jeff" Anderson & Jeffrey Bailey To Board; Demands Disclosure Of Any High-Pressure Sales Calls To Certain Large Shareholders, Including Any Offers, Promises Or Assurances Made To Shareholders To Sway Vote At Last Minute

Rogers Communications&nbsp;(TSX:<a class="ticker" href="https://www.benzinga.com/stock/RCI#TSX">RCI</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>)&nbsp;today announced it has received clearance from the Competition Bureau to proceed with the acquisition of Bell's 37.5% stake in Maple Leaf Sports &amp; Entertainment.
Rogers and Bell received a&nbsp;"no-action letter"&nbsp;on December 12, 2024, from the Bureau, indicating that the Commissioner of Competition does not intend to challenge Rogers acquisition of Bell's interest in MLSE.
The deal is subject to league approvals and approval from the CRTC.

TSX:RCI

Rogers Provides Update On Its Acquisition Of Bell's 37.5% Stake In Maple Leaf Sports & Entertainment; Rogers And Bell Received A "No-Action Letter" On December 12, 2024, From The Bureau, Indicating That The Commissioner Of Competition Does Not Intend To Challenge Rogers Acquisition Of Bell's Interest In MLSE

Flagstar Financial Announced That It Named Lee Smith CFO, Effective December 27, 2024

WIIM

MEDIROM Healthcare Technology shares are trading higher after the company announced that its subsidiary, MEDIROM MOTHER Labs, has raised a total of JPY 260.3 million to date in its Series A financing round.

Edesa Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDSA#NASDAQ">EDSA</a>) reported quarterly losses of $(1.93) per share which beat the analyst consensus estimate of $(2.15) by 10.23 percent.

Earnings Beats

EDSA

Edesa Biotech FY 2024 GAAP EPS $(1.93) Beats $(2.15) Estimate

Financing

MEDIROM Healthcare Technology's MEDIROM MOTHER Labs Subsidiary Raised To Date Aggregate Total Of JPY260.3 Million In Its Series A Financing Round

<a href="https://www.globenewswire.com/Tracker?data=apTePpSm9SCnLgNoSFUqZtG9UrZt644IclDaOPNiVriy0Crhz8PfzCMxcqk7DdTupdwUf_Hl-WSDav56x59xKYG7Tp19pBlS7suSSVXUzTErAW3PulQJdpDlhV0G9xe5">Outlook Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that following an internal strategic review, the management team and Board of Directors have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing its efforts to commercially launch LYTENAVA&#x2122; (bevacizumab gamma) for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) and supporting the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA&#x2122; to the U.S. Food and Drug Administration (FDA).
Lawrence Kenyon, Interim Chief Executive Officer and Chief Financial Officer commented, "In light of the current financial market conditions and the Company's strategic focus on the commercial launch of LYTENAVA&#x2122; (bevacizumab gamma) in Europe, following Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, we conducted a strategic review with the goal of preserving capital and extending our cash runway as long as possible. As a result of this process, we identified potential efficiencies and are taking immediate cost-saving measures, including a 23% reduction in our workforce representing $1.4 million in annual savings excluding the costs of the reduction in workforce. As we look ahead, we remain steadfast in our belief in the potential of ONS-5010/LYTENAVA&#x2122; to meet the global needs of retina specialists, patients, and payers and are dedicated to advancing our regulatory and commercial efforts."
The Company recently announced that the National Institute for Health and Care Excellence (NICE) has recommended LYTENAVA&#x2122; (bevacizumab gamma) as an option for the treatment of wet AMD. LYTENAVA&#x2122; (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and UK and has an initial 10 years of market exclusivity. Separately, upon receipt of the full efficacy and safety results for the NORSE EIGHT clinical trial in the United States, which are expected in January 2025, Outlook Therapeutics plans to resubmit its BLA application for ONS-5010 in the first quarter of calendar 2025. Previously, the Company announced that ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA in the NORSE EIGHT trial. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010.

OTLK

Outlook Therapeutics Streamlines Operations, Cuts Workforce By 23% For $1.4M Annual Savings, Aims To Launch LYTENAVA In EU/UK, Prepares BLA Resubmission In Q1 2025 Despite NORSE EIGHT Trial Not Meeting Endpoint; LYTENAVA Receives NICE Recommendation, 10-Year Market Exclusivity

Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) has outperformed the market over the past 15 years by 1.89% on an annualized basis producing an average annual return of 13.82%. Currently, Canadian Pacific Kansas has a market capitalization of $69.81 billion. 
Buying $1000 In CP: If an investor had bought $1000 of CP stock 15 years ago, it would be worth $7,058.66 today based on a price of $74.80 for CP at the time of writing.
<h3>Canadian Pacific Kansas's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734125409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Canadian Pacific Kansas 15 Years Ago Would Be Worth This Much Today

The Good Shroom reports Q2 results

TGSHF

Events

Press Releases

The Good Shroom Co Inc. to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in association with Small Cap Discoveries on Thursday, September 26, 2024 at 10:00 AM PST

TSXV:MUSH

Good Shroom Co

Comments

Good Shroom Co

Good Shroom Co (TGSHF) Forecast

Good Shroom Co (OTC:TGSHF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga